electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
11 oct. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
26 sept. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
electroCore to Participate in the LD Micro Main Event XVI Conference
25 sept. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger,...
electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference
21 sept. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger,...
gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)
25 juil. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer reviewed...
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
18 juil. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
electroCore Provides Select Second Quarter 2023 Financial Guidance
11 juil. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today provided select preliminary...
gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms
06 juil. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its gammaCore non-invasive...
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
12 avr. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue...
electroCore Announces Remittance of Annual License Fee from Teijin for Certain Exclusive Rights in Japan
11 avr. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Teijin...